Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
In order to test the suggestion that antipsychotic drugs act by blocking dopamine receptors in the brain, the direct effects of such neuroleptic drugs were tested on the stereospecific binding of [3H]dopamine and of [3H]haloperidol to rat brain striata and their subfractions. The stereospecific component of binding was defined as that amount of [3h]dopamine or [3H]haloperidol bound in the presence of (-)-butaclamol (an inactive drug) minus that bound in the presence of (+)-butaclamol (a potent neuroleptic drug); 100 nM butaclamol was used for the [3H]haloperidol assay, while 1 muM butaclamol was used for the [3H]dopamine assay. Various antipsychotic drugs inhibited this stereospecific component in both the dopamine and haloperidol assays. These inhibitory potencies correlated with the clinical doses used for controlling schizophrenia.
D000818:Animals; D001665:Binding Sites; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000378:metabolism*; D006801:Humans; D008297:Male; D051381:Rats; D011955:Receptors, Drug; D012559:Schizophrenia / Q000188:drug therapy; D013574:Synaptosomes / Q000378:metabolism; D014149:Tranquilizing Agents / Q000378:metabolism* / Q000627:therapeutic use
D011955:Receptors, Drug; D014149:Tranquilizing Agents; D006220:Haloperidol; D004298:Dopamine